# MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma

> **NCT06377540** · PHASE2 · RECRUITING · sponsor: **Masonic Cancer Center, University of Minnesota** · enrollment: 28 (estimated)

## Conditions studied

- Autologous Stem Cell Transplant
- Classic Hodgkin Lymphoma

## Interventions

- **DRUG:** Pembrolizumab
- **PROCEDURE:** Autologous stem cell transplant
- **DRUG:** Carmustine
- **DRUG:** Etoposide
- **DRUG:** Cytarabine
- **DRUG:** Melphalan

## Key facts

- **NCT ID:** NCT06377540
- **Lead sponsor:** Masonic Cancer Center, University of Minnesota
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-04
- **Primary completion:** 2026-09-01
- **Final completion:** 2027-09-01
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2025-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06377540

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06377540, "MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06377540. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*